Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise

The Australian Financial Review10-31

Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479753368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 02:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479753368","market":"hk","top_or_hot":-1,"title":"Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise","media":"The Australian Financial Review","content":"<div>\n<p>Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within...</p>\n\n<a href=\"https://www.afr.com/street-talk/cochlear-backed-medtech-epiminder-seeks-200m-val-in-pre-ipo-raise-20241030-p5kmh3\">Source Link</a>\n\n</div>\n","source":"afr_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 02:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.afr.com/street-talk/cochlear-backed-medtech-epiminder-seeks-200m-val-in-pre-ipo-raise-20241030-p5kmh3><strong>The Australian Financial Review</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within...</p>\n\n<a href=\"https://www.afr.com/street-talk/cochlear-backed-medtech-epiminder-seeks-200m-val-in-pre-ipo-raise-20241030-p5kmh3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.afr.com/street-talk/cochlear-backed-medtech-epiminder-seeks-200m-val-in-pre-ipo-raise-20241030-p5kmh3","article_id":"2479753368","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479753368","pubTimestamp":1730311200,"sourceInfo":{"source_id":"afr_stock","name":"The Australian Financial Review"},"weMediaInfo":null,"summary":"Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within inches of gaining Food and Drug Administration approvals and is turning its mind to an IPO.Traditional epilepsy equipment which Epiminder seeks to disrupt.  Loading...","collect":0,"end_time":0,"defaultTopTitle":"afr.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"Cochlear支持的医疗技术Epiminder寻求IPO前融资2亿美元val","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1},"content_text":"Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within inches of gaining Food and Drug Administration approvals and is turning its mind to an IPO.Traditional epilepsy equipment which Epiminder seeks to disrupt.   Loading...","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479753368"}